



Lantheus Announces Closing of Strategic Collaboration and Exclusive License Agreements for the Commercialization of PNT2002 & PNT2003 with POINT Biopharma

Dec 20, 2022

NORTH BILLERICA, Mass., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus") (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow disease, today announced the closing of the strategic collaboration agreements previously announced on [November 14, 2022](#) between Lantheus and POINT Biopharma Global Inc., a company accelerating the discovery, development and global access to life-changing radiopharmaceuticals. Closing of the agreements was subject to customary closing conditions, including the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Act.

About Lantheus

With more than 65 years of experience in delivering life-changing science, Lantheus is committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow disease. Lantheus is headquartered in Massachusetts and has offices in New Jersey, Canada and Sweden. For more information, visit www.lantheus.com.

Contacts:

Lantheus

Mark Kinarney
Vice President, Investor Relations
978-671-8842
ir@lantheus.com

Melissa Downs
Senior Director, Corporate Communications
646-975-2533
media@lantheus.com



Source: Lantheus Holdings, Inc.